NASDAQ:VYGRVoyager Therapeutics Stock Price, Forecast & News

$12.29

-0.30 (-2.38 %)

(As of 05/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$11.83

Now: $12.29▼

$12.75

50-Day Range

$8.91

MA: $11.15▼

$13.01

52-Week Range

$6.26

Now: $12.29▼

$28.79

Volume349,171 shs

Average Volume365,817 shs

Market Capitalization$457.08 million

P/E RatioN/A

Dividend YieldN/A

Beta1.91

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

4.4 Analyst's Opinion

Consensus Rating
Voyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.56, Voyager Therapeutics has a potential upside of 51.0% from its current price of $12.29.
Amount of Analyst Coverage
Voyager Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Voyager Therapeutics has received 341 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Voyager Therapeutics has received 292 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Voyager Therapeutics has received 53.87% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote “Outperform” if you believe VYGR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Voyager Therapeutics does not currently pay a dividend.
Dividend Growth
Voyager Therapeutics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,664.00 in company stock.
Percentage Held by Insiders
Only 22.90% of the stock of Voyager Therapeutics is held by insiders.
Percentage Held by Institutions
80.51% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Voyager Therapeutics are expected to grow in the coming year, from ($2.72) to ($2.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Voyager Therapeutics is -10.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Voyager Therapeutics is -10.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Voyager Therapeutics has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.74 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VYGR

Previous Symbol

CUSIPN/A

CIK1640266

Webwww.voyagertherapeutics.com

Phone857-259-5340

Debt

Debt-to-Equity RatioN/A

Current Ratio3.76

Quick Ratio3.76

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$104.39 million

Price / Sales4.38

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.14 per share

Price / Book5.74

Profitability

EPS (Most Recent Fiscal Year)($1.21)

Net Income$-43,600,000.00

Net Margins-34.70%

Return on Equity-40.11%

Return on Assets-11.29%

Miscellaneous

Employees123

Outstanding Shares37,191,000

Market Cap$457.08 million

Next Earnings Date8/14/2020 (Estimated)

OptionableOptionable

Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

How has Voyager Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Voyager Therapeutics' stock was trading at $9.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VYGR shares have increased by 30.3% and is now trading at $12.29. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Voyager Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Voyager Therapeutics.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Voyager Therapeutics.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics Inc (NASDAQ:VYGR) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.66) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.79) by $0.13. The company had revenue of $18.07 million for the quarter, compared to the consensus estimate of $8.70 million. Voyager Therapeutics had a negative return on equity of 40.11% and a negative net margin of 34.70%. View Voyager Therapeutics' earnings history.

What price target have analysts set for VYGR?

10 Wall Street analysts have issued 12-month price targets for Voyager Therapeutics' stock. Their forecasts range from $13.00 to $27.00. On average, they anticipate Voyager Therapeutics' share price to reach $18.56 in the next twelve months. This suggests a possible upside of 51.0% from the stock's current price. View analysts' price targets for Voyager Therapeutics.

What are Wall Street analysts saying about Voyager Therapeutics stock?

Here are some recent quotes from research analysts about Voyager Therapeutics stock:

1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (5/9/2020)
2. Nomura Securities analysts commented, "Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future." (8/13/2019)
3. HC Wainwright analysts commented, "Our current target is based on a 12-year DCF analysis primarily focused on VY-AADC in PD. Our DCF analysis is based on: beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2030." (8/12/2019)

Has Voyager Therapeutics been receiving favorable news coverage?

Media coverage about VYGR stock has been trending somewhat positive on Thursday, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Voyager Therapeutics earned a daily sentiment score of 1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutVoyager Therapeutics.

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,310,000 shares, a decrease of 5.2% from the April 30th total of 3,490,000 shares. Based on an average trading volume of 382,700 shares, the short-interest ratio is presently 8.6 days. Currently, 14.0% of the shares of the company are sold short. View Voyager Therapeutics' Current Options Chain.

Who are some of Voyager Therapeutics' key competitors?

Some companies that are related to Voyager Therapeutics include SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Cortexyme (CRTX), Twist Bioscience (TWST), Regenxbio (RGNX), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), I-Mab (BDTX), Mesoblast (MESO), Beam Therapeutics (BEAM), Translate Bio (TBIO), Coherus Biosciences (CHRS), NanoString Technologies (NSTG), Passage Bio (PASG) and Sorrento Therapeutics (SRNE). View all competitors.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), Crispr Therapeutics (CRSP), Regenxbio (RGNX), TG Therapeutics (TGTX), NVIDIA (NVDA), AbbVie (ABBV), Editas Medicine (EDIT), ImmunoGen (IMGN), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:

Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)
Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)
Mr. G. Andre Turenne, CEO, Pres & Director
Dr. Krystof Bankiewicz M.D., Ph.D., Founder
Dr. Guangping Gao Ph.D., Founder

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.48%), State Street Corp (3.68%), Clearbridge Investments LLC (3.25%), Bank of New York Mellon Corp (2.42%), Foresite Capital Management IV LLC (1.39%) and Federated Hermes Inc. (1.28%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Glenn Pierce, James A Geraghty, Matthew P Ottmer, Neurocrine Biosciences Inc, Omar Khwaja and Robert W Hesslein. View institutional ownership trends for Voyager Therapeutics.

Which major investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Foresite Capital Management IV LLC, Morgan Stanley, GSA Capital Partners LLP, Deutsche Bank AG, Bailard Inc., Wellington Management Group LLP, and Two Sigma Advisers LP. Company insiders that have sold Voyager Therapeutics company stock in the last year include Allison Dorval, Andre Turenne, Matthew P Ottmer, Omar Khwaja, and Robert W Hesslein. View insider buying and selling activity for Voyager Therapeutics.

Which major investors are buying Voyager Therapeutics stock?

VYGR stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, BlackRock Inc., Clearbridge Investments LLC, Hancock Whitney Corp, Needham Investment Management LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., and Trexquant Investment LP. Company insiders that have bought Voyager Therapeutics stock in the last two years include Glenn Pierce, James A Geraghty, and Neurocrine Biosciences Inc. View insider buying and selling activity for Voyager Therapeutics.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $12.29.

How big of a company is Voyager Therapeutics?

Voyager Therapeutics has a market capitalization of $457.08 million and generates $104.39 million in revenue each year. The company earns $-43,600,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is www.voyagertherapeutics.com.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff